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                                                                               ABSTRACT 
 
CORRELATION OF FACILITY OF AQUEOUS OUTFLOW AND INTRAOCULAR 
PRESSURE IN VARIOUS STAGES OF DIABETIC RETINOPATHY – A HOSPITAL BASED 
STUDY 
 
Key words: tonography, diabetic retinopathy, aqueous outflow facility. 
 
AIM: 
To determine the correlation of aqueous outflow facility and intraocular pressure in various stages 
of diabetic retinopathy and to determine their relationship with glycemic control of the patient. 
 
MATERIALS AND METHODS: 
A total of 150 diabetic  patients were included in our study. It included 25 patients with No Diabetic 
retinopathy, 25 patients each in mild, moderate,severe, very severe Non proliferative Diabetic 
Retinopathy, 25 patients in Proliferative Diabetic Retinopathy. Patients with bilaterally symmetrical 
stage  of DR were selected for our study. Patients with other systemic complications, closed angle, 
secondary glaucoma, known case of glaucoma, ocular surgery in the past were excluded. 
All patients underwent detailed systemic and ocular examination,applanation tonometry,tonography, 
perimetry. Systemic examination for glycemic status with FASTING, POST PRANDIAL BLOOD 
SUGAR, HbA1C.patients with significantly low aqueous outflow facility were followed up every 3 
months in this one year study. 
RESULTS: 
Average aqueous outflow facility was found to be decreased with                                   
advance in the stage of diabetic retinopathy in both the eyes.  
It  was found to be statistically significant ( RE p-Value=0.000,  
LE p-Value= 0.000 ). 
Mean intraocular pressure was found to be increased with advance                             
in the stage of diabetic retinopathy  in both the eyes.  
It was found to be statistically significant ( RE p-Value= 0.000,  
LE p-Value = 0.006). 
Average aqueous outflow facility was found to be decreased with increase in mean 
HbA1C  level  in  various  stages  of  diabetic  retinopathy  in  both  eyes.  (  RE  r=  -0.761,  p-
Value=0.000, LE r= -0.759, p-Value= 0.000 ) .  
 Average  IOP  was  found  to  be  increased  with  increase  in   mean  HbA1C  level  in  
various stages of diabetic retinopathy in both the eyes. It was found to be statistically 
significant.(REr=0.628, p-Value= 0.000, LE  r= 0.608, p-Value= 0.000).   
Among the 150 patients 43 patients had significantly reduced aqueous outflow facility at 
their first visit examination. Hence they were followed up every 3 months. 
           Among 43 patients advised follow up ,  22 patients attended regular follow up of 
maximum 3 visits  every 3 months in this one year study period.  
            At  the  end  of  this  one  year  period  2  of  the  22  patients  were  found  to  develop  early  
glaucomatous  field  changes   in  their   visual  field.  They  were  also  found  to  have  continued  
poor glycemic control ( HbA1C > 6.5),  significantly low aqueous outflow facility and 
intraocular pressure slightly increased compared to the  initial recording.  
CONCLUSION: 
This study has revealed that performing tonography and detecting  patients with significantly 
low aqueous outflow facility can be a guidance for early diagnosis of development of  POAG 
rather than relying on IOP alone .  
Hence tonography can be used as one of the examination techniques  along with IOP 
measurement , optic nerve head evaluation and perimetry,  for early  identification of  risk of 
developing POAG due to reduced aqueous outflow facility in diabetic patients with advanced 
stages of diabetic retinopathy. 
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PART – I 
  
   INTRODUCTION 
Diabetic retinopathy and glaucoma are among the leading causes 
of visual impairment. If  not diagnosed and treated earlier  they can lead 
to irreversible visual impairment and blindness. Various methods are 
under evaluation for early diagnosis and treatment of these conditions.  
           Glaucoma is a chronic progressive optic neuropathy caused by a 
group of ocular conditions which lead to damage to optic nerve with loss 
of visual function. Increase in intraocular pressure is the most 
commonly known risk factor1. 
           Intraocular pressure is determined by the balance between 
aqueous production and aqueous outflow. Imbalance of the two can lead 
to increased intraocular pressure, which is one of the reversible risk 
factors for glaucoma. Aqueous outflow is one of the important 
determinants of intraocular pressure. 
           Quantification of aqueous outflow facility brings us close to the 
basic mechanism of abnormal aqueous humor dynamics in glaucoma 
than measurement of intraocular pressure alone2. Intraocular pressure 
reflects the combined effect of three factors: aqueous production , 
aqueous outflow and episcleral venous pressure, only one of which is 
known to be abnormal in most types of glaucoma. 
           Diabetes Mellitus is one type of metabolic disorder7. It is 
characterised by chronic hyperglycemia which leads to long term 
damage and dysfunction of various organs like eyes, kidney, nerves, 
heart, blood vessels,etc.. In India  about 35 million people with diabetes 
mellitus are present till date. 
           Diabetes mellitus being an important ocular risk factor, besides 
causing diabetic retinopathy and other ocular manifestations also affects 
the intraocular pressure by affecting the outflow facility6. 
           When the cause for an abnormal pressure is under  issue, 
tonography remains a very informative and surprisingly convenient  
procedure for determination of outflow facility. Tonography can be done 
as an outpatient procedure using non- invasive methods. 
           Since aqueous outflow is one of the important determinants of 
intraocular pressure – the present study is undertaken to correlate the 
aqueous outflow facility with the diabetic patients at various stages of  
diabetic retinopathy24, also taking into account their glycemic control. 
This study was done among patients treated at Stanley medical college 
and hospital, at Chennai. 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
The French Dr Antoine- demours (1818) made the first excellent 
description of glaucoma with raised intraocular pressure.  
          Dr William McKenzie (1835) mentioned the essential feature of 
raised eye tension. He was a Scottish clinician . 
           In 1873 Leber discovered that, aqueous humor  is  the result of an 
ongoing dynamic process involving the eye and the circulatory system5. 
Grant introduced tonography in 19502,23. 
           An electronic schiotz tonometer  that enhanced precision of 
pressure induced flow was discovered by V. Mueller3 .                
           The definition of glaucoma as a disease of optic nerve 
(glaucomatous optic neuropathy) caused by many factors which were 
called as risk factors was described  by  Dr. drance ( 1973) .                     
           The name Schlemm’s canal is given  after Friedrich Schlemm  
(1795–1858), a German anatomist5. 
           Aretaeus belongs to Cappadocia. He was an eminent physician in 
a Pneumatic school. He  introduced the term diabetes (the Greek verb 
diabaino = pass through) to define the condition in which a large 
quantity of urine passes through kidney in 2nd century AD .     
             Friederick Banting and Charles Best in 1921 extracted  insulin 
from the pancreas.                   
           In 1856 - Diabetic macular changes was reported first by Eduard 
Jaeger .                              
          In 1876, Wilhelm Manz -  reported proliferative changes in 
diabetic retinopathy and the importance of tractional retinal detachments 
and vitreous haemorrhages.  
           Arthur James Ballantyne   - diabetic retinopathy represents a 
unique vasculopathy. 
           Beaver Dam Study in 1994  analysed the relationship between 
open angle glaucoma and late onset diabetes.           
           Los angeles Latino Eye Study in 2008 concluded that presence 
of  Type2DM  was  associated  with  increased  risk  of  having  open 
angle glaucoma. 
          Matsuoka et al, in 2012 reported that there is significantly higher 
IOP in diabetic patients and positive correlation of IOP with HbA1c 
levels in patients with diabetic retinopathy.  
 
 
 
 
 
 
 
 
 
 
 
 
           AQUEOUS OUTFLOW PATHWAY ANATOMY 
 Aqueous outflow pathway is located at the angle of the anterior 
chamber3.  
 It has the following parts:                      
1. Trabecular Meshwork 
 Uveal Meshwork 
 Corneoscleral Meshwork 
 Juxta Canalicular Meshwork 
2. Schlemm’s Canal 
3. Collector Channels 
4. Episcleral Veins  
1. Trabecular Meshwork: 
  It is a sieve like structure. It bridges the scleral sulcus, and 
converts it into a tube and accomodates schlemm’s canal44. It consists of 
Hyaluronic acid (GAG) & Chondroitin, Heparin, dermatan and keratan 
sulphates . It also consists of Fibronectin, elastin, laminin, collagen  
(I, III, IV, V, VI), myosin. 
¾ Uveal meshwork:                         
It is the innermost part. It extends from iris root and ciliary body 
to schwalbe’s line. It is cord like and 2-3 layers thick. The arrangement 
of it’s trabeculae creates irregular openings 25-75 µm size.      
Trabeculae have 3 concentric layers 
1. Central collagenous core 
2. Middle basement membrane 
3. Enclosing trabecular cell 
¾ Corneoscleral Meshwork: 
 It is the middle portion. It extends from the scleral spur to the 
lateral wall of the scleral sulcus . It consists of flat sheets of trabeculae 
with elliptical openings (5-50µ). Openings become smaller as the 
trabecular sheets approach schlemm’s canal (1-2µ). 
 
 
¾ Juxtacanalicular Meshwork: 
 It is the outermost portion ,offers the normal resistance to 
aqueous outflow2. Layers of connective tissue (2-5 layers) lined  on 
either side by endothelium are present . This narrow part (2-20µ) 
connects corneo-scleral meshwork with schlemm’s canal. 
                              AQUEOUS OUTFLOW PATHWAY  
 
 
 
 
Schlemm’s Canal28: 
It is an oval channel lined by endothelium present  
circumferentially in the scleral sulcus. Its inner wall cells are  spindle 
shaped and irregular. It contains giant vacuoles. Outerwall cells are 
smooth and flat. Numerous openings on the outer wall form the collector 
channel.  Torus or lip like thickening and septa are present to keep the 
canal open. 
2. Collector Channels: 
These are intra scleral aqueous vessels. They are 25-35 in 
number, leave at oblique angles and end in episcleral veins.They are 
lined by vascular endothelium. They have no valves. 
These intrascleral aqueous vessels can be divided into two 
systems. 
a. Direct system (8 Large Vessels): 
It has short Intrascleral course and terminates in episcleral veins. 
On slit lamp examination it appears as clear vessels with aqueous called 
Aqueous veins by Ascher. They are also called as laminated veins of 
Goldmann. 
b. Indirect system : 
   Numerous fine channels drain into 
¾  Deep intrascleral plexus 
¾  Mid intrascleral plexus 
¾  Episcleral venous plexus  
     Ultimately they end in episcleral veins. 
3. Episcleral Veins: 
 They drain into Anterior Ciliary Vein Æ Superior Ophthalmic 
Vein Æ Cavernous Vein. 
                               
 
 
 
 
 
AQUEOUS HUMOUR DYNAMICS 
             Aqueous humor dynamics includes aqueous inflow  
(ie. Formation) and outflow ( ie. Drainage)2.  Aqueous humor flows 
from posterior to anterior chamber  through pupil against slight 
physiological resistance. 
             In the anterior chamber there is convection (thermal) current due 
to temperature gradient between anterior and posterior part of the 
anterior chamber. 
             The aqueous humor in the posterior part of anterior chamber 
moves up along warm iris and in the anterior part moves down along the 
cooler cornea.      
From the anterior chamber , aqueous is drained out by two routes: 
x Trabecular (conventional) outflow 
x Uveoscleral (unconventional) outflow 
 
  
 
 Transmission electron micrograph of the inner wall of  
                       Schlemm’s canal (SC) of a human eye: 
 
 
Trabecular  outflow: 
           It is the main outlet for aqueous from anterior chamber. About 
90% of the aqueous is drained out via this route. Free flow occurs from 
trabecular meshwork upto inner wall of schlemm’s canal which provides 
least resistance45. 
 Mechanism of transport across inner wall of schlemm’s canal: 
Vacuolation theory is the most accepted view. According to it 
transcellular spaces exist in the endothelial cells forming inner wall of 
schlemm’s canal. These open as a system of vacuoles46 and  pores  ,  
primarily in response to pressure , and transport the aqueous from the 
juxtacanalicular connective tissue to schlemm’s canal. 
From schlemm’s canal48 the aqueous is transported via 25-35 
external collector channels into the episcleral veins by direct and 
indirect systems. A pressure gradient between intraocular pressure and 
intrascleral venous pressure ( about 10 mm hg) is responsible for 
unidirectional flow of aqueous. 
 
 
Uveoscleral outflow: 
 It is responsible for about 10% of the  total aqueous  outflow. 
Aqueous passes across the ciliary body into the suprachoroidal space 
and is drained by the venous circulation in the ciliary body , choroid and 
sclera. 
 
 
 
GLAUCOMA 
               Glaucoma  is a group of  disorders characterised by 
progressive optic neuropathy resulting in characteristic appearance of 
the optic disc and a specific pattern of irreversible visual field defects 
that are associated frequently but not invariably with raised intraocular 
pressure. Thus intraocular pressure is the most common but not the only 
risk factor for the development of glaucoma. 
              Glaucoma in greek means clouded or blue-green hue. 
Classification: 
           Glaucoma may be classified as follows: 
1. Congenital and developmental glaucomas: 
x Primary congenital glaucoma( with no associated anomalies) 
x Developmental glaucoma(associated with  anomalies) 
2. Primary adult glaucomas: 
x Primary open angle glaucoma 
x Primary angle closure glaucoma 
x Primary mixed mechanism glaucoma 
3. Secondary glaucomas. 
Glaucomatous ocular damage can be due to the following 
pathogenesis: 
  As per the definition of glaucoma all glaucomas are characterised 
by progressive optic neuropathy. Progressive  optic neuropathy results 
from death of retinal ganglion cells in a typical pattern which results in 
characteristic optic disc appearance and visual field defects. 
Pathological mechanism of retinal ganglion cell death3: 
           It occurs due to pathological block in transport of growth factors( 
neurotropins) from the brain to the retinal ganglion cells. This initiates a 
damaging cascade , and the cell is unable to maintain its normal 
function. They undergo apoptosis and also trigger apoptosis of adjacent 
cells. 
          Retinal ganglion cell death is associated with loss of retinal nerve 
fibres. As this extends beyond the normal physiological overlap of 
functional zones the characteristic optic disc changes and specific visual 
field defects become apparent overtime. 
 
Etiological factors: 
Factors involved in retinal ganglion cell death and hence 
glaucomatous optic neuropathy are: 
A. Primary insults: 
1) Raised intraocular pressure ( Mechanical Theory): It causes 
mechanical stretch on lamina cribrosa Æ axonal deformation and 
ischemia by altering capillary blood flow. So neurotrophins are not 
able to reach in sufficient amount to retinal ganglion cells for their 
survival. 
2) Pressure independent factors ( Vascular Insufficiency Theory):           
Factors affecting vascular perfusion of optic nerve head in the 
absence of raised intraocular pressure are also implicated in 
glaucomatous optic neuropathy14. These factors include- 
x Defective autoregulatory mechanism of blood flow 
x Vasospasm 
x Systemic hypotension 10– especially nocturnal dips in patients 
on anti- hypertensive medications. 
x Other factors- acute blood loss, abnormal coagulability 
profile9. 
B. Secondary insults (excitotoxicity theory): 
Degeneration of neurons is also driven by certain toxic factors. 
They are glutamate( excitatory toxin), oxygen free radicals, or nitric 
oxide. They are released when retinal ganglion cells undergo death due 
to primary insults. 
Optic nerve head changes in glaucoma3: 
         There is no first sign of glaucomatous nerve damage nor  there is 
a single pattern of damage in optic disc. Rather there are many patterns 
by which the nerve becomes damaged. 
1. Features related to loss of neuroretinal rim tissue: notching,  
pseudopit, diffused rim loss. 
2. Features related to development, enlargement or alteration of the 
cup: asymmetry of cup size, overpass cupping, vertical extension, 
concentric enlargement of the cup, temporal unfolding, nasal 
cupping,  C:D ratio increase,  laminar dot sign. 
3. Features related to change of color of optic disc tissue: pallor and 
cupping. 
4. Features related to change of blood vessels of the disc: optic disc 
haemorrhage, nasalization of vessels, bayonetting of vessels, baring 
of circumlinear vessels . 
5. Peripapillary area Beta zone atrophy. 
 
 
 
  
 
 
 
 
 
 
OPTIC NERVE HEAD CHANGES 
 
  Advanced glaucomatous cupping Localized rim loss inferiorly     
   
 
 
 
 
 
 
 
 
GRADING OF ANGLE DEPTH 
 There are three standard grading system for anterior chamber 
angle depth. 
1. Scheie grading system 
2. Shaffer grading system 
3. Spaeth grading system 
SCHEIE GRADING SYSTEM: 
Grade Parts visible 
1 Angle is widely open 
2 Angle permits visibility to scleral spur  
3 Angle permits visibility to trabecular 
meshwork only 
4 Angle is appositionally closed to Schwalbe’s 
line 
 
 
 
SHAFFER GRADING SYSTEM4: 
Grade Angle width 
in degrees 
configuration Structures visible 
4 40 Wide open  SL, TM, SS, CBB 
3 30 Open angle SL, TM, SS 
2 20 Moderately 
narrow 
SL, TM 
1 10 Very narrow SL only 
S < 10 Slit angle No angle structures 
seen 
0 0 Closed No  angle 
structures seen 
 
        SL – schwalbe’s line, TM – Trabecular meshwork,  
        SS – Scleral spur , CBB – Ciliary body band 
  
 SPAETH GRADING SYSTEM OF ANTERIOR CHAMBER 
ANGLE 
Site of iris insertion: 
Anterior to schwalbe’s line = A 
Behind Schwalbe’s line = B 
At scleral  spur = c 
Normal deep angle recess = D 
Extremely deep angle recess = E 
Angle width in degrees: 
10, 20 , 30, 40, 50 
Peripheral iris curvature: 
Concave = q 
Flat = r 
Steep ( convex ) = s 
 
PERIMETRY  AND VISUAL FIELDS IN GLAUCOMA 
  Perimetry  is the procedure for determining the extent of the 
visual fields4. 
It can be classified as follows: 
x Kinetic  and static perimetry: 
x Peripheral and central field charting: 
x Manual and automated perimetry: 
1. Kinetic perimetry:  Here a stimulus is moved from a peripheral 
non-seeing point towards the centre till it is perceived to establish the 
isopters. Eg: Confrontation method, Lister’s perimetry, Tangent 
screen scotometry, Goldmann perimetry. 
2. Static perimetry: Here a stimulus is presented at a predetermined 
position for a preset time with varying luminance in the field of 
vision. Eg: Goldmann perimetry, Friedman perimetry, Automated 
perimetry. 
 
 
Automated perimetry: 
    It is computer assisted and tests visual fields by a static method. 
 They automatically test suprathreshold and threshold stimuli and 
quantify depth of visual field defect. 
 Commonly used automated perimeters are – Octopus, Field 
Master, Humphrey Field Analyser. 
VISUAL FIELD LOSS IN GLAUCOMA: 
Generalised loss: 
 Diffused loss of sensitivity. 
Increased variability. 
Hemifield asymmetry. 
Localized loss: 
 Early defects: paracentral scotoma,nasal step, temporal wedge 
defect. 
      Late defects: arcuate scotoma, annular scotoma, altitudinal 
defect. 
Advanced field loss: 
Retained central vision and/or temporal island. 
Split of fixation. 
Loss of central island and or temporal field. 
  
AQUEOUS  OUTFLOW  PATHWAY CHANGES  IN  
DIABETES MELLITUS 
  Individuals with diabetes are found to have high frequencies of 
glaucoma and increased intraocular pressure11. It has been ascribed that 
there is increased accumulation of extracellular matrix components like 
fibronectin and glycosaminoglycans in the aqueous outflow pathway.  
 The trabecular meshwork in the chamber angle is found to 
function as a self-cleaning filter and to participate in the regulation of 
aqueous outflow and control of intraocular pressure.  
Connective tissue in the trabecular meshwork beam contains 
extracellular matrix proteins like fibronectin, laminin, heparin sulfate, 
and collagen types 1,3,4,5,6.  
          Davis et al42 have reported that the glucose levels in aqueous 
humor of patients with diabetes was significantly higher. Trabecular 
meshwork cells undergo  biochemical alterations when  they  are  
exposed to such amount of  high concentration of  glucose in aqueous 
humor . 
 There occurs fibronectin over expression at both mRNA and 
protein level in trabecular meshwork18. The high glucose level also 
reduces trabecular meshwork cell proliferation as in vascular endothelial 
cells. The chemoattractant potential of fibronectin in aqueous humor 
causes decrease in trabecular meshwork cellularity47. 
           The  regulation of aqueous outflow in the trabecular meshwork is 
impaired by these changes  in diabetes16 ,leading to reduced aqueous 
outflow facility and hence increased intraocular pressure. 
           Fibronectin overexpression  is induced by high glucose . This 
may be a common biochemical link  contributing to two main changes: 
1. Thick vascular basement membrane in diabetic microangiopathy 
2. Altered structural content, resiliency, reduced cellularity and 
hence blockage of aqueous outflow in trabecular meshwork. 
          Elevated IOP in diabetes  could be explained in part by higher 
insulin resistance  and chronic hyperglycemia .  In the eye insulin   acts 
as a vasodilator through nitric oxide. Insulin and IOP can have some 
common effect.  
 Nitric oxide decreases IOP acutely by increasing trabecular 
outflow facility . IOP falls acutely in response to nitric oxide induced 
contraction of cell volume. The  mediators for this process are soluble 
guanylate cyclase, PK G, and Ca2+ -activated K+ channel21 .  In  fact,  
these regulatory elements may associate insulin with changes in outflow 
facility. Reduction in insulin and hence nitric oxide decreases this 
outflow facility. 
           Further  there is reduced antioxidant51 in diabetes at the level of 
trabecular meshwork as in all other parts of the body .  Hence there is 
early trabecular damage leading to increased outflow resistance49. 
          Due to the accumulation of advanced glycation end products 
(AGE) there will be Oxidative stress19. Advanced glycation end 
products  (AGE) are nonenzymatic protein cross-links. They may 
interfere with the structural properties of the protein.  This leads to some 
deleterious effects. 
 In the meshwork, tissue transglutaminase is present and due to its 
advanced glycation it causes increased TGF 1,2 which  causes 
polymerization of fibronectin leading to irreversibly cross-linked 
extracellular matrix proteins. The pathological changes due to AGE 
products in the outflow pathways and role of AGE in glaucoma is being 
still under research. 
           Several molecules21 (TGFE2, VEGF, endothelin, PAI, and 
soluble CD44) are elevated in the aqueous humor of POAG when 
compared to normal aqueous humor. These molecules may influence 
trabecular cells to change their  normal phenotype ,ie. trabecular cells 
could respond to elevated aqueous humor levels of TGF-E2 by secreting 
additional extracellular matrix molecules. 
                                         
 
 
 
 
 
 
 
 
  
 
 
 
TONOMETRY 
              It is an equipment used for  measurement of intraocular  
pressure  by utilizing  physical natures of the eye ,without the need to 
cannulate the eye1 . 
               The physical characters of the normal cornea determine the 
limits of accuracy of tonometry 
CLASSIFICATION : 
1. APPLANATION TONOMETRY4  
x  Goldmann Applanation Tonometry  
x Perkin’s  Applanation Tonometry 
x Non-Contact Tonometry  
2. INDENTATION TONOMETRY  
x  Schiotz Tonometer  
x  Pneumotonometer  
x  Tono-Pen  
3.  REBOUND TONOMETRY  
Schiotz tonometry: 
With the Schiotz tonometer ,various  standard weights are applied 
to the cornea via a plunger. Cornea is indented by a  plunger and the 
deformation of the globe is recorded from a scale. The  IOP  is then 
calculated from these two values. 
          The plunger moves in the center of  the instrument in a vertical 
plane and passes through a curved footplate that sits on top of the cornea 
with the patient in the supine position.  
 SCHIOTZ TONOMETER 
 
 
 
 
 
 
 
 
 
PRINCIPLE OF SCHIOTZ TONOMETER 
 
  
  
 
 
 
 
 
           A  “holder” fixes the footplate on the cornea .But it  allows  the 
plunger  and attached weights to move in the vertical direction freely. 
            On placing the tonometer on the eye, there occurs distention of 
the globe due to corneal indentation. This corneal indentation and globe 
distention both are indicated by the scale reading. 
           Friedenwald's formula relates this distention to the IOP. The 
formula requires  a constant  “K” or the  “coefficient of ocular rigidity,”.  
 Ocular rigidity: 
 Ocular or sclera rigidity is an expression of strechability of the 
eye in response to increase in intraocular pressure.                         
           The value of  coefficient of scleral rigidity ( K ) for an individual  
eye was determined by Friedenwald2. It was calculated from two 
tonometric scale readings using different weights. Then Friedenwald's  
“nomogram” allows one to graphically calculate K.  The average 
normal value was 0.0215 as calculated by him. 
           At present , there are simplified tables which   gives  the K and 
IOP values from the paired scale readings on the involved eye . 
Limitations : 
           If the true K of the eye is higher than the average K, true IOP will 
be overestimated.  
           A false-low IOP will occur if the true K is less than the  
average K. 
 
                        Friedenwald's  “nomogram”   
 
 
 
 High ocular rigidity has been reported in : 
x high hyperopia,   
x chronic glaucoma,  
x vasoconstrictor therapy.  
 
 
                                APPLANATION TONOMETER 
            
 
 
 
                   IMBERT FICK’S LAW 
 
 
 
 
 
 
x Goldmann applanator: 
Applanation tonometry is based on the Imbert-Fick’s principle. 
It states that for an ideal sphere the pressure (P) inside the sphere is 
equal to the force (F) required to applanate (flatten) its surface, divided 
by the area (A) of flattening: 
               P = F/A      or        F = PA. 
The ideal sphere will be thin-walled, dry and flexible. The cornea 
has none of these three. Hence  there are two other significant forces at 
work.  
The force of capillary attraction (T) between the tonometer head 
and the tear film is additive to the external force. In addition, a force  
(C), is needed to flatten the cornea which is comparatively inflexible. 
Hence,  
              F = PA , becomes  
              F + T  =  PA + C , or 
              P =( F + T - C) / A 
The   Goldmann applanator is designed so that A  will be 7.35 
mm 2.  
To achieve this, the diameter of flattening of the cornea should be 
3.06 mm .  
With this value for A, the opposing forces of capillary attraction 
and corneal inflexibility cancel out. In addition, with this value for A the 
IOP in millimeters of mercury (mmHg) is equal to ten times the force 
applied to the cornea which is given  in grams. 
The tonometer  “tip,” a tapered plastic cylinder containing a 
biprism, is the contact point with the cornea. The tip is connected by a 
rod to the body of the tonometer which contains an adjustable spring 
that provides the appropriate applanating force. The force is altered 
manually with a knob that contains a scale indicating the force applied 
in grams. At the end-point, the reading in grams is multiplied by 10 to 
convert to millimeters of mercury. 
The biprism splits the image of the circle of contact into two 
semicircles. When these semicircles just touch at their inner margin, a 
3.06-mm diameter circle of cornea is applanated.  
Precautions: 
x Valsalva maneuvers, or breath holding  should be avoided.  
x The semicircles should be clear with distinct margins.  
x Wider, blurred semicircles result in false-high readings as 
does vertical misalignment.  
x Under estimation of  the true IOP  will occur if fluorescein 
is not used. 
x False pressure readings occur in corneal astigmatism.  
OTHER TONOMETERS: 
Perkins applanation tonometer 
Draeger applanation tonometer 
Mackay- Marg tonometer3 
Tono – pen tonometer 
Pneumotonometer 
Noncontact Air- puff tonometer 
Dynamic contour tonometer 
Ocular response analyser 
 
 
 
 
 
 
 
 
 
TONOGRAPHY 
  Tonography is a dynamic test of the ability of the eye to recover 
from the elevation of intraocular pressure induced by schiotz tonometry. 
Such recovery occurs primarily through an increased rate of 
aqueous humor flow out of the eye. Hence the test is a measure of 
facility of aqueous humor outflow2. In glaucoma there is reduced 
aqueous outflow facility as there is increased resistance to aqueous 
outflow. 
Thus quantification of aqueous outflow facility brings us close to 
the basic mechanism of abnormal aqueous dynamics in glaucoma than 
measurement of intraocular pressure alone.  
Methodology: 
Tonography was introduced by Grant in the year 195023. 
Aqueous humor outflow is measured by various techniques each 
with its own limitations and advantages. 
 
 
TRABECULAR OUTFLOW FACILITY: 
Some  resistance to the aqueous outflow is given by  
juxtacanalicular part of trabecular meshwork. This  resistance is  needed 
so that a steady-state of  IOP is maintained normally. The trabecular 
meshwork’s compliance can be measured with this trabecular outflow 
facility28.  
Techniques: 
1) Non -Invasive techniques 
a) Tonography - with schiotz tonometer, 
b) Tonography with pneumatic tonometer. 
c) Fluorophotometry25 . 
2) Invasive techniques-  
a) constant pressure perfusion technique,  
b) flow-to-blood method with radioisotope infused in the anterior 
chamber.  
 
Tonography - with schiotz tonometer: 
Here, under topical  anaesthesia  Probe  of schiotz  tonometer’s is 
placed on the cornea of the subject for  4 minutes , patient being in 
supine position .The  IOP initially rises due to  the weight placed on the 
cornea, but, in course of time, the pressure gradually decreases. This is 
due to the  following reason: Aqueous humor will  drain  at an increased 
rate via the drainage pathways from the anterior chamber . The decrease  
in IOP during the procedure is thought  to be  mainly  due to  increased 
drainage of aqueous humor via the trabecular meshwork from the 
anterior chamber. 
The outflow facility  is determined from reference tables using 
initial reading and reading of schiotz at the end of 4 minutes 
(Annexure). While  testing if  there is  little decrease in IOP ,  then the 
fluid flow rate  would be small as in reference tables36, and hence there 
will be less trabecular outflow facility. In ocular hypertension with or 
without glaucoma this finding usually occurs . 
Disadvantage: varies with change in ocular rigidity (pneumatic 
tonometer is less affected by it). 
 
Fluorophotometry : 
Here by measuring the rate of disappearance of a tracer from the 
anterior chamber Aqueous flow (F) is determined26 . Then IOP and 
aqueous flow are reduced by medication .  The drug-induced change in 
IOP (IOP2 - IOP1) is then measured with tonometry.  The change in 
aqueousflow  (F2 - F1) is then measured by fluorophotometry.  
Outflow facility is calculated by Equation : 
C = (F2 - F1)/(IOP2 - IOP1). 
 Invasive Methods:                    
The two-level, constant-pressure perfusion technique is an 
invasive procedure that is used to measure outflow facility in research 
animals27. 
These are mostly used for enucleated eyes of humans. But in 
clinical studies they cannot be used . 
          The flow-to-blood method is the most reliable  technique from 
which we can measure trabecular outflow facility. After infusing a 
radioactive isotope into the anterior chamber at a set pressure (IOP1) & 
time , the rate of its accumulation in the blood is assumed to be 
trabecular outflow (F1). Then  at a different level of  pressure  (IOP2) 
infusion of isotope is done  , and the new rate of it’s accumulation in the 
blood is assumed to be a new trabecular outflow (F2). Then outflow 
facility determined as for fluorophotometry. 
UVEOSCLERAL OUTFLOW  FACILITY : 
Overview: 
Uveoscleral outflow is another  drainage route  for aqueous 
humor from the anterior chamber. Here it leaves into the ciliary muscle. 
Here it diffuses  out of the eye in many directions . The route of this 
outflow is poorly defined.  Also it is  a pressure independent outflow 
pathway . 
Measurement techniques for Uveoscleral Outflow : 
Non Invasive Method : 
The noninvasive means to assess uveoscleral outflow (Fu) is by 
calculation using  the following equation : 
                            Fu = F - C(IOP-Pv) 
Fluorophotometry measures Aqueous humor flow (F). IOP is 
measured  by tonometry. Episcleral  venous pressure (Pv) is measured 
by venomanometry. 
Invasive methods:  
Compared to the  mathematical calculation these procedures are 
more direct. But in clinical studies they cannot be used . 
 Intracameral tracer method: 
A  radioactive or fluorescent tracer is infused into the anterior 
chamber for a specific period of time at a predetermined pressure. 
Uveoscleral  outflow  is determined from the  total amount of tracer 
found in the uvea and sclera during the specified interval of time.  
Indirect isotope method: 
In this procedure a radioactive tracer is infused into the anterior 
chamber. Then  the rate by which  of the tracer’s appear in the blood 
(trabecular outflow) and tracer’s disappear from the anterior chamber 
(aqueous flow)  is monitored .  The difference between aqueous flow 
and trabecular outflow is Uv. 
 
COMPLICATIONS IN EYE DUE TO  
DIABETES MELLITUS7,29 
1. Diabetic retinopathy13 
2. Cataract29 
3. Anterior ischemic optic neuropathy 
4. Diabetic papillopathy 
5. Ocular movement disorders 
6. Glaucoma6,12 – primary open angle glaucoma , neovascular 
glaucoma 
7. Retinal vein occlusion7 
8. Retinal artery occlusion 
9. Corneal diseases 
                      
 
 
DIABETIC RETINOPATHY 
Diabetic retinopathy refers to retinal changes seen in patients with 
diabetes mellitus. 
           It’s incidence has increased due to increase in life expectancy of 
patients with diabetes. It is becoming one of the leading causes of 
blindness. 
Etiopathogenesis: 
Risk factors for diabetic retinopathy are: 
 Duration of diabetes 
 Sex 
 Poor metabolic control 
 Heredity 
 Pregnancy 
 Hypertension 
 Anemia  
 Nephropathy  
 Others- smoking, obesity, hyperlipidemia. 
Pathogenesis: 
It is a microangiopathy affecting retinal precapillary arterioles, 
capillaries and venules.  
Capillaropathy: 
I. Degeneration and loss of pericytes 
II. Proliferation of endothelial cells 
III. Thickening of basement membrane and occlusion 
Hematological changes: 
I. Deformation of erythrocytes and rouleaux formation 
II. Changes in RBC and hence defective oxygen transport 
III. Increased plasma viscocity 
IV. Increased stickiness and aggregation of platelets 
These changes result in microvascular occlusion and leakage. 
Retinal vascular changes in diabetic retinopathy15: 
1) Capillaries: 
Occlusion, dilation, 
microaneurysms,abnormal permeability. 
2) Arterioles: 
Narrowing of terminal arterioles, 
Occlusion ,Sheathing. 
3) Veins:  
Tortuosity, Looping , 
 Beading , Sausage like segmentation. 
 
 
 
 
 
 
Classification :  
There are various types of classifications of Diabetic 
 Retinopathy. 
It can be classified as: 
I. Non- proliferative diabetic retinopathy: 
x Mild 
x Moderate 
x Severe 
x Very severe 
II. Proliferative diabetic retinopathy ( PDR ) 
III. Diabetic maculopathy 
IV. Advanced diabetic eye disease 
 
 
 
 
                                           MILD NPDR 
 
 
 
 
 
 
 
 
 
 
 
 
MODERATE NPDR 
 
 
 
  SEVERE NPDR 
 
   
 
 
 
 
 
 
 
 
 
PDR 
  
 
 
 
 
 
 
 
 
 
 
      The classification used in the Early Treatment Diabetic 
Retinopathy Study (Modified Airlie House Classification) is widely 
used now-a-days4. 
 
Non proliferative diabetic retinopathy: 
 
Category Clinical features 
No DR  - 
 Mild  
(Stage1NPDR) 
Atleast one microaneurysm or intraretinal 
haemorrhage. 
Hard & soft exudates may or may not be present. 
Moderate  
(Stage2NPDR) 
Moderate microaneurysms/ intraretinal haemorrhage. 
Early mild IRMA. Hard/soft exudates may or may not 
be present. 
Severe  
(Stage3NPDR) 
Any one of the following ( 4-2-1  rule): 
Four quadrants of severe microaneurysms/intraretinal 
haemorrhages. 
Two quadrants of venous beading. 
One quadrant of IRMA changes. 
Very severe 
(Stage4NPDR) 
Any two of the following: ( 4-2-1 rule): 
Four quadrants of severe microaneurysms/intraretinal 
haemorrhages. 
Two quadrants of venous beading. 
One quadrant of IRMA changes. 
 
Proliferative diabetic retinopathy: 
Category Clinical features 
Mild to moderate New vessels on the disc  
( NVD ) or new vessels elsewhere (NVE) . But 
extent insufficient to meet the high risk criteria 
High risk New vessels on the disc  
( NVD ) greater than 1/3 the disc area. 
Any NVD with vitreous or preretinal 
haemorrhage. 
NVE > ½ the disc area with vitreous or preretinal 
haemorrhage. 
Advanced diabetic Vitreous haemorrhage,  
eye disease tractional RD, tractional retinoschisis, rubeosis 
iridis. 
 
 
 
 
 
Diabetic maculopathy:  
Clinico – angiographically it can be classified as: 
Category  Clinical features 
Focal  Microaneurysms, hard exudates, haemorrhages, 
macular edema arranged in circinate pattern. 
Diffused  Diffused retinal edema, thickening in posterior 
pole, few hard exudates. 
Ischemic  Marked visual loss + Microaneurysms, hard 
exudates, few haemorrhages, mild or no macular 
edema 
Mixed  Combined feature of ischemic & exudative 
maculopathy. 
 
               GLAUCOMA IN DIABETES MELLITUS 
x POAG16,17: 
Glaucoma is more common  in diabetics (5%). But it is only 2% 
in the general population  . In diabetics  the risk of glaucoma22 is  higher 
than in nondiabetic by about 1.6–4.7 times. In the Blue Mountains32 and 
Beaver Dam Eye30 studies it was found that  diabetics were twice as 
likely to have glaucoma as those without.  
Microvascular damage from diabetes could impair blood flow to 
the anterior optic nerve. In the  posterior ciliary circulation 
autoregulation  is impaired. This may increase the risk of glaucomatous 
optic neuropathy. Concomitant cardiovascular risk factors  
(e.g., hypertension)  also increases risk. 
But the basic mechanism of increased intraocular pressure 
appears to be decreased aqueous outflow due to increased resistance at 
trabecular meshwork31. 
 
 
 x NEOVASCULAR GLAUCOMA: 
 Proliferative retinopathy is  the most common cause of this type 
of secondary glaucoma35. Proliferative diabetic retinopathy causes about 
32 and 43% of neovascular glaucoma cases. 
                        
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
PART - II 
 
 
 AIM OF THE STUDY 
1. To determine aqueous outflow facility in various stages of diabetic 
retinopathy. 
2. To determine the correlation of  aqueous outflow facility in various 
stages of diabetic retinopathy24. 
3. To determine the correlation of  aqueous outflow facility with 
glycemic control of the patients by analyzing their HbA1C  level. 
4. To determine the influence of poor glycemic control  in diabetic 
populations  with diabetic retinopathy on development of primary 
open angle glaucoma in them by causing reduction in aqueous 
outflow facility. 
5. To analyse the importance of  monitoring tonography for early 
diagnosis of primary open angle glaucoma in diabetic retinopathy 
patients ,in addition to measurement of intraocular pressure , 
monitoring glaucomatous field changes and optic nerve head 
changes. 
 
INCLUSION CRITERIA: 
Clinical criteria for selection of patient for study was: 
1. Diabetic patients with and without  diabetic retinopathy getting 
treatment at Department Of  Diabetology,  Stanley medical 
college, Chennai. 
2. Patients with Bilaterally symmetrical stage of diabetic 
retinopathy. 
3. Patients with no other ocular diseases 
4. Patients with no other systemic illness other than diabetes. 
5. Patients with open angles in gonioscopy. 
EXCLUSION CRITERIA: 
1. Patients with other systemic illness other than diabetes mellitus. 
2. Patients who underwent previous ocular surgery. 
3. Patients with known history of glaucoma with/ without 
medications. 
4. Patients diagnosed to have glaucoma on initial examination at 
first visit. 
5. Patients with secondary glaucoma, narrow angles. 
6. Patients with other ocular diseases, dense cataract, opaque media. 
7. Patients with high myopia. 
8. Patients on systemic medications altering aqueous outflow 
facility. 
9. Patients with no other systemic complications of  diabetes 
mellitus. 
10. Patients who had undergone laser treatment for diabetic 
retinopathy. 
  
MATERIALS AND METHODS 
This study was performed on 150 diabetic patients, at Department 
Of Ophthalmology, Government Stanley Medical college, Chennai, 
during a period of one year from November 2012  to october 2013. 
 This study was done in accordance with the rules of ethical 
committee. All the subjects were explained about the nature of the 
procedure and an informed consent was obtained.   
Materials: 
  Patients falling inside the inclusion criteria were included  for 
this study. 
 A total of 150 patients were selected for this study. It included 25 
patients in each of the following group- No DR, Stage 1 NPDR, Stage 2 
NPDR, Stage3 NPDR, Stage 4 NPDR, PDR. 
 A detailed medical history was collected from all the participants 
and they underwent a thorough physical examination, relavant 
laboratory tests regarding their diabetic status and complete ocular 
examinations. 
The laboratory tests included:  
x The estimation of haemoglobin, 
x Fasting and post prandial plasma glucose levels,  
x Glycated haemoglobin (HbA1C) levels  
x Random urine examination for the microalbuminuria34. 
The concentration of HbA1C which was formed through                                                            
the non-enzymatic attachment of glucose to haemoglobin, was 
commonly considered to reflect the integrated mean glucose levels over 
the previous 8–12 weeks, the time period being dictated by the 120 day 
lifespan of the erythrocyte 38. 
The  ocular examinations included : 
x Assessment of visual acuity,  
x Slit-lamp examination of anterior segment, 
x Detailed fundus examination, 
x Gonioscopy for grading of angles,  
x Intraocular pressure  ( with Goldmann Applanation Tonometer ),  
x Tonography ( with schiotz tonometer), 
x Automated perimetry.  
        APPLANATION TONOMETRY 
 
 
 
 
 
 
 
 
  
 
                                          Automated perimetry 
 
 
 
 
 
 
 
 
 
 
 
  
  
                                  TONOGRAPHY  WITH  SCHIOTZ TONOMETER 
 
  
 
 
 
 
Patients with significantly low aqueous outflow facility were  
reviewed every 3 months. These  patients were subjected to all the 
needed glaucoma screening investigations and tonography at each visit . 
Patients glycemic control was also monitored at each visit. 
 A maximum of 3 review visits were done for these group of     
patients in this study period. Other patients were asked for review based 
on their diabetic status. 
 Patients data at each visit were recorded and compared at each 
follow up visits. 
 All the datas were entered in Microsoft Excel and analysed using 
SSPS PACKAGE( statistical analysis of social science version -16).  
ANOVA test was done to estimate p-value. According to this test 
P-value was kept significant at < 0.05.  
The correlation between HbA1C level and intraocular pressure, 
and also between HbA1C level and aqueous outflow facility in various 
stages of diabetic retinopathy was analysed using Pearson’s correlation 
test and the datas were plotted in scatter plot diagram. The correlation 
was assessed based on this  ‘r ’ value. 
                                     OBSERVATIONS 
Table 1 : Age and sex distribution of  patients  
selected in our study group: 
Group Age in 
years 
Male female Total 
1 30 – 40 6 12 18 
2 41 – 50 16 18 34 
3 51 – 60 23 38 61 
4 >60 19 18 37 
Total  64 86 150 
Percentage  42.66% 57.33%  
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Maximum number of subjects were in the age group of 51-60 
years.( Table 1) 
        
  
TABLE 2: Relationship  between Stage of diabetic  
retinopathy and aqueous outflow facility in microlit/min/mm Hg: 
 No DR  Stage1 
NPDR 
Stage2 
NPDR 
Stage3 
NPDR 
Stage4 
NPDR 
PDR p- 
Value*  
Average 
aqueous 
outflow 
facility RE 
 
0.2624 
 
0.2500 
 
0.2420 
 
0.2288 
 
0.2148 
 
0.1960 
 
0.000 
Average 
aqueous 
outflow 
facility LE 
 
0.2592 
 
0.2496 
 
0.2472 
 
0.2340 
 
0.2132 
 
0.1996 
 
0.000 
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Average aqueous outflow facility is found to be decreased with 
advance in the stage of diabetic retinopathy in both the eyes. It is found 
to be statistically significant ( RE p-Value=0.000, LE p-Value= 0.000 ). 
(Table 2) [*- ANOVA Study was used and p-Value kept significant at 
 < 0.05 ] 
  
TABLE 3 : Relationship  between Stage of diabetic retinopathy  
and intraocular pressure  in mm Hg : 
 No DR Stage1 
NPDR 
Stage2 
NPDR 
Stage3 
NPDR 
Stage4 
NPDR 
PDR p- 
Value* 
 Mean IOP 
in RE 
15.12 
 
16.16 16.72 17.12 17.28 18.08 0.000 
Mean IOP 
in LE 
16.00 16.56 16.64 16.88 17.20 17.84 0.006 
   
 
   Mean intraocular pressure was found to be increased with 
advance in the stage of diabetic retinopathy  in both the eyes.  
It was found to be statistically significant ( RE p-Value= 0.000,  
LE p-Value = 0.006) (Table 3). [*- ANOVA Study was used and  
p-Value kept significant at < 0.05 ] 
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 TABLE 4: Relationship between HbA1C level and various stages  
of diabetic retinopathy: 
Stage of DR Mean HbA1C level 
No DR  5.866 
Stage1 NPDR 6.1 
Stage2 NPDR 6.44 
Stage3 NPDR 6.732 
Stage4 NPDR 7.128 
PDR 7.592 
p-Value* 0.000 
 
 
 
 
 
  
            Mean HbA1C level was found to be high with advance in the 
stage of diabetic retinopathy. It was found to be statistically significant 
 ( p-Value= 0.000) ( Table 4). [*- ANOVA Study was used and p-Value 
kept significant at < 0.05 ] 
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 TABLE 5: Association between  Mean HbA1C and aqueous  
outflow facility in microlit/min/ mm Hg  in various stages of DR: 
Stage of  
DR 
No 
DR 
Stage1 
NPDR 
Stage2 
NPDR 
Stage3 
NPDR 
Stage4 
NPDR 
PDR 
r- Value 
p-Value* 
Mean 
HbA1C 
level 
 
5.866 
 
6.1 
 
6.44 
 
7.32 
 
7.128 
 
7.592 
 
Average 
aqueous 
outflow 
facility 
RE 
 
0.2624 
 
0.2500 
 
0.2420 
 
0.2288 
 
0.2148 
 
0.1960 
 r= -0.761 
p=0.000 
Average 
aqueous 
outflow 
facility 
LE 
 
0.2592 
 
0.2496 
 
0.2472 
 
0.2340 
 
0.2132 
 
0.1996 
r= -0.759 
p= 0.000 
  
 
 
 
 Scatter plot showing correlation between Mean HbA1C and 
aqueous outflow facility in various stages of DR in Right Eye : 
 
 
 
 
 
 
Scatter plot showing correlation between Mean HbA1C and 
aqueous outflow facility in various stages of DR in Left Eye : 
 
Average aqueous outflow facility was found to be decreased  
with increase in mean HbA1C level in various stages of diabetic 
retinopathy in both eyes. ( RE r= -0.761, p-Value= 0.000, LE r= -0.759,  
p-Value= 0.000 ) ( Table 5 ) [*- ANOVA Study was used and p-Value 
kept significant at < 0.05 ] 
 
 
 TABLE 6: Association between mean HbA1C level and IOP in 
mm Hg    in various stages of DR: 
Stage of  
DR 
No DR  Stage1 
NPDR 
Stage2 
NPDR 
Stage3 
NPDR 
Stage4 
NPDR 
PDR r- Value 
p-Value* 
Mean 
HbA1C 
level 
 
5.866 
 
6.1 
 
6.44 
 
7.32 
 
7.128 
 
7.592 
 
 Mean 
IOP in 
RE 
15.12 
 
16.16 16.72 17.12 17.28 18.08 r= 0.628 
p= 0.000 
Mean 
IOP in 
LE 
16.00 16.56 16.64 16.88 17.20 17.84 r= 0.608 
p= 0.000 
 
 
 
 
 
 
 Scatter plot showing correlation between Mean HbA1C and  Mean 
IOP in various stages of DR in Right Eye : 
 
 
 
 
 
Scatter plot showing correlation between Mean HbA1C and Mean 
IOP in various stages of DR in Left Eye : 
 
 
                 Average IOP was found to be increased with increase in  
mean HbA1C level in various stages of diabetic retinopathy in both  
the eyes. It was found to be statistically significant. ( RE r= 0.628,  
p-Value= 0.000, LE r= 0.608, p-Value= 0.000).( Table 6 ) [*- ANOVA 
Study was used and p-Value kept significant at < 0.05 ] 
  
 TABLE 7:Association of Mean ocular rigidity in relation  
to retinal status: 
 No 
DR  
Stage1 
NPDR 
Stage2 
NPDR 
Stage3 
NPDR 
Stage4 
NPDR 
PDR p- 
Value*  
Mean 
ocular 
rigidity 
RE 
 
0.0217 
 
0.0216 
 
0.0216 
 
0.0217 
 
0.0216 
 
0.0216 
 
0.783 
Mean 
ocular 
rigidity LE 
 
0.0217 
 
0.0216 
 
0.0216 
 
0.0216 
 
0.0216 
 
0.0216 
 
0.814 
  
              There was no significant difference in ocular rigidity in various 
stages of diabetic retinopathy in both eyes. (RE p-Value= 0.783,  LE p-
Value= 0.814 ).( Table 7) [*-  ANOVA  Study  was  used  and  p-Value  
kept significant at < 0.05 ] 
 
 
RESULTS 
A total of 150 subjects  were  recruited in our study. They were in 
the  age group ranging from 30 yrs  and above. 
All the recruited subjects were within the inclusion criteria for our 
study. 
The following were the results of our study: 
          Average aqueous outflow facility was found to be decreased with 
advance in the stage of diabetic retinopathy in both the eyes.  
It  was found to be statistically significant ( RE p-Value=0.000,  
LE p-Value= 0.000 ).[TABLE 2] 
Mean intraocular pressure was found to be increased with 
advance in the stage of diabetic retinopathy  in both the eyes.  
It was found to be statistically significant ( RE p-Value= 0.000,  
LE p-Value = 0.006). [TABLE 3] 
 Mean HbA1C level was found to be high with advance in the 
stage of diabetic retinopathy. It was found to be statistically significant  
( p-Value= 0.000). Average aqueous outflow facility was found to be 
decreased with increase in mean HbA1C level in various stages of 
diabetic retinopathy in both eyes. ( RE r= -0.761, p-Value= 0.000,  
LE r= -0.759, p-Value= 0.000 ) . [TABLE 4] 
 
OPTIC NERVE  HEAD CHANGES  IN GLAUCOMA 
 
 
 
 
 
 
 
                           PERIMETRY WITH GLAUCOMATOUS FIELD DEFECTS 
 
 
 
 
 
 
 
  
  PERIMETRY WITH GLAUCOMATOUS FIELD DEFECTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Average IOP was found to be increased with increase in  mean 
HbA1C level in various stages of diabetic retinopathy in both the eyes. 
It was found to be statistically significant. ( RE r=0.628,  
p-Value= 0.000, LE  r= 0.608, p-Value= 0.000). [TABLE 5] 
Patients were asked for follow up based on their findings.           
        Among the 150 patients 43 patients had significantly reduced 
aqueous outflow facility at their first visit examination. Hence they were 
followed up every 3 months. 
           Among 43 patients advised follow up ,  22 patients attended 
regular follow up of maximum 3 visits  every 3 months in this one year 
study period.  
 They underwent the needed ocular and systemic examinations in 
all the 3 visits and the results were compared . 21 patients did not attend 
complete follow up as per advice.  
            At the end of this one year period 2 of the 22 patients were found 
to develop early glaucomatous field changes  in their  visual field. They 
were also found to have continued poor glycemic control ( HbA1C > 
6.5),  significantly low aqueous outflow facility and intraocular pressure 
slightly increased compared to the  initial recording. [ FOLLOW UP 
CHART IN ANNEXURE] 
 
 
 
 
 
 
 
 
 
 
 
 
  
                            DISCUSSION 
Our study reveals that aqueous outflow facility is getting reduced 
significantly with advance in the stage of diabetic retinopathy and also 
with  poor glycemic control . 
           Our study also reveals that intraocular pressure is at a 
comparatively higher level in patients with poor glycemic controls  
(HbA1C > 6.5) and  also with advance in the stage of diabetic 
retinopathy. 
Beaver Dam Study30 in 1994 concluded that presence of open 
angle glaucoma is increased in people with late onset diabetes.           
           Los angeles Latino Eye Study in 2008 concluded that presence of 
Type2DM was associated with increased risk of having open angle 
glaucoma. 
 Arora Vn,Prasad Vn in 1989  have also reported that IOP was 
comparatively increased in patients with  diabetes mellitus  with diabetic 
retinopathy than in patients without diabetic retinopathy. Our study also 
concludes that  intraocular pressure is higher in diabetic patients with 
advance in stage of  diabetic  retinopathy. 
Matsuoka et al43, in 2012 reported that there is significantly 
higher IOP in diabetic patients with advance in the stage of diabetic 
retinopathy and also with poor glycemic control. Our study also 
concludes the same. 
 Mean 
Iop in 
the 
following 
stage of 
DR 
Matsuoka 
et al study 
Arora 
Vn 
study 
      Our study 
RE LE 
 
 
 
Observations 
 
No DR 15.6 
 
 
18.17 15.12 16.00 
Mild to 
Moderate 
NPDR 
15.7 20.98 to 
21.99 
16.16 to 
16.72 
16.56 to 
16.64 
Severe 
NPDR 
15.00 22.18 17.12 16.88 
PDR 18.00 15.98 18.00 17.84 
 
Inference  
 Mean IOP is  
significantly 
increased in 
patients 
with 
diabetic 
retinopathy 
( p-value < 
0.001 
Mean 
IOP is 
increased 
in 
patients 
with 
advance 
in stage 
of NPDR 
Mean  IOP was 
significantly higher 
with advance in the 
stage of diabetic 
retinopathy in both 
eyes. ( RE p-value = 
0.000, LE p -Value  = 
0.006 ) 
 
 
          Anandalakshmi et al8 in 2011 reported that mean IOP was higher 
in patients with DM and also in patients with poor glycemic control. Our 
study also concludes that IOP is significantly higher in patients with 
poor glycemic control.                                   
 
 
Anandalakshmi et al 
study 
Our study 
RE LE 
Observation  Mean Iop with  
mean  
HbA1C                17.32 
Of  6.00 
Mean Iop with 
mean  
HbA1C Of  
5.866 }=15.12  
Mean Iop with 
mean 
 HbA1C Of 
5.866 }= 16.00 
Iop with mean  
HbA1C                20.98 
Of 7.42 
Iop with mean  
HbA1C Of 
7.592 }= 18.08                          
Iop with mean 
 HbA1C Of 
7.592 }= 17.84 
p- Value = 0.001 
r- Value = 0.82 
p- Value = 
0.000 
r- value = 
0.628 
p- value = 
0.000 
r – value = 
0.608 
Inference  Mean IOP is diabetic patients was found to be increased  
with increase in mean HbA1C level    
( ie. with poor glycemic control ). 
 
  
          
The reason for association between POAG and diabetes mellitus 
is still to be completely elucidated. It has been reported in as early as 
1984 by Davies et al that glucose level in aqueous humor is higher in 
patients with diabetes mellitus.  
It has been found that the high glucose level in aqueous humor in 
patients with diabetes mellitus leads to fibronectin upregulation in 
trabecular meshwork20 . 
This compromises trabecular meshwork cellularity50, resiliency 
and alters its structural content. Hence aqueous outflow facility is 
reduced at  Trabecular Meshwork level leading to raised IOP and finally 
patients will be at risk of POAG33.  
           Arora Vn,Prasad Vn in 1989 have reported that aqueous outflow 
facility is reduced in patients with advance in stage of  diabetic  
retinopathy, especially ( NPDR > PDR). Our study  also concludes that 
aqueous outflow is significantly reduced with advance in the  stage of 
diabetic retinopathy. 
 
 
  
 
 
 
 
Mean 
Aqueous 
outflow 
facility in 
microlit/min/ 
mm Hg  in the 
following 
stages of DR 
 
 
 Arora Vn 
study 
 
 
         Our study 
RE LE 
Observations No DR 0.265 0.2624 0.2592 
 Mild DR 0.201 0.2500 0.2496 
 Moderate DR 0.231 0.2420 0.2472 
 Severe DR 0.220 0.2288 0.2340 
 PDR 0.315 0.1960 0.1996 
Inference   Facility of 
aqueous 
outflow is 
getting 
reduced 
with 
advance in 
stage of 
NPDR 
Facility of aqueous 
outflow is getting 
reduced significantly 
with advance in the 
stage of DR  
( RE p-Value = 0.000, 
LE p-Value = 0.000 ) 
 
  
Also due to disturbance in microcirculation in Diabetes 
Mellitus39, these  patients are at early risk of ONH damage40,41.  Also 
Retinal Ganglion Cell death occurs earlier in them due to altered 
metabolism. 
           Our study found that when patients with significantly reduced 
aqueous outflow facility with poor glycemic control were regularly 
followed up over this one year period,  2 patients of the 22 patients 
developed early glaucomatous field defects at follow up visits compared 
to normal fields in their initial visits. They were also observed to have 
continued poor glycemic control and reduced aqueous outflow facility in 
this study period.  
 Hence our study reveals that monitoring aqueous outflow facility 
also, while screening for early detection of primary open angle 
glaucoma will  be a useful guide along with other parameters of 
glaucoma evaluation which is routinely done. 
  
CONCLUSION 
Glaucoma is one of the preventable causes of irreversible visual 
impairment, if diagnosed and treated  at earlier stages37. Diabetes has 
been shown to be one of the risk factors for POAG. 
          Hence early screening of diabetic  patients with appropriate 
techniques, will help to detect people at risk to develop POAG  .Hence 
they can be followed up regularly with appropriate treatment when 
needed. 
 Since aqueous outflow facility is also one of the important 
component in determining the intraocular pressure , it will be more 
appropriate to measure it , especially in diabetics.   
          Tonography  with schiotz tonometer is a simple, inexpensive and 
non- invasive procedure. It can be done as an outpatient procedure. 
         It can be done even in peripheral health centres to detect  people at 
risk to develop POAG so that they can be referred in time to higher 
centres for early treatment and prevention of glaucomatous optic nerve 
damage. 
This study has revealed that performing tonography and detecting  
patients with significantly low aqueous outflow facility can be a 
guidance for early diagnosis of development of  POAG rather than 
relying on IOP alone .  
Hence tonography can be used as one of the examination 
techniques  along with IOP measurement , optic nerve head evaluation 
and perimetry,  for early  identification of  risk of developing POAG due 
to reduced aqueous outflow facility in diabetic patients with advanced 
stages of diabetic retinopathy. 
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PROFORMA 
Name:                                         Age:                                     Sex: 
OP/IP no: 
Presenting illness: 
Past history: 
            Diabetes history- 
            Treatment history- 
            H/O other medical illness- 
Family history: 
            Diabetes-                                                     Glaucoma-      
Details of examination: 
General examination: 
Ocular examination: 
                                                              Right eye                         left eye 
1.Eyelids 
2.Eyelashes  
3.Eom 
4.Conjunctiva 
5.Cornea 
6.Pupil 
7.Iris 
8. Anterior chamber 
9.Lens 
10.Visual acuity: 
          Distance  
          Near  
11.   Colour vision 
12.   Retinoscopy: 
13.  PMT: 
14. Fields with automated perimetry: 
15. IOP with applanation tonometer :  
16. Gonioscopy: 
17.Fundus findings: 
Direct ophthalmoscope: 
Indirect ophthalmoscope: 
+90 D examination: 
 
 
Aqueous outflow measurement with schiotz tonometer: 
 RE 
5.5 gms 
LE 
5.5 gms 
RE 
7.5 gms 
LE 
7.5 gms 
Scale reading at 0 
mts 
    
Scale reading at 4 
mts 
    
Facility of aqueous 
outflow 
    
 
Ocular rigidity based on Modified Fridenwald’s Nomogram:   
 RE LE 
IOP with 5.5 gms   
IOP with 10.00 gms   
Ocular rigidity   
  
Inference:                                             RE                      LE 
1. Stage of diabetic retinopathy: 
2. Mean Intraocular pressure:  
3. Mean Aqueous outflow facility: 
4.  Ocular rigidity: 
Advice : 
                                        ABBREVIATIONS 
 
 S.NO                -  SERIAL NUMBER 
 DM        -  DIABETES MELLITUS 
 DR         -  DIABETIC RETINOPATHY 
 AQ         -  AQUEOUS  
 IOP        -  INTRAOCULAR PRESSURE 
 RE         -  RIGHT EYE 
 LE         -  LEFT EYE 
 M          -  MALE 
 F            -  FEMALE 
 YRS      -  YEARS 
 MTH     -  MONTHS 
 OHA     -  ORAL HYPOGLYCEMIC AGENTS 
 ISN       -  INSULIN 
 NPDR   -  NON PROLIFERATIVE DIABETIC 
RETINOPATHY 
 NPDR1  -  MILD NON PROLIFERATIVE 
DIABETIC RETINOPATHY 
 NPDR2  –  MODERATE NON PROLIFERATIVE 
DIABETIC RETINOPATHY 
 NPDR3  –  SEVERE  NON PROLIFERATIVE 
DIABETIC RETINOPATHY 
 NPDR4  -   VERY SEVERE NON 
PROLIFERATIVE DIABETIC 
RETINOPATHY 
 PDR      -  PROLIFERATIVE  DIABETIC 
RETINOPATHY 
 CSME   -  CLINICALLY SIGNIFICANT 
MACULAR EDEMA 
 FCSME  -  FOCAL CLINICALLY SIGNIFICANT 
MACULAR EDEMA 
 DCSME  -  DIFFUSED  CLINICALLY  
SIGNIFICANT MACULAR EDEMA 
 IOP -  INTRAOCULAR PRESSURE 
 V - VISIT 
 LFU  –  LOST FOLLOW UP 
 M LIT  –  MICROLITRE 
 MM HG  –  MILLIMETRE OF MERCURY 
 YRS  –  YEARS 
 AQ  – AQUEOUS  
 POAG - PRIMARY OPEN ANGLE  
   GLAUCOMA 
 
 
 
S .NO NAME
Age in 
yrs/ Sex
Duration of DM 
from Diagnosis Treatment HbA1c
RE    LE     RE LE      RE     LE    RE     LE
1 dhanalakshmi 46/F 32 YRS OHA NPDR4 NPDR4 0.19 0.18 18 20 0.022 0.0218 7.3
2 kasthuri 65/F 1 MTH OHA NPDR1 NPDR1 0.22 0.2 18 18 0.0214 0.0214 6.9
3 gunasekar 50/M 16 YRS INSULIN PDR+CSME PDR 0.17 0.19 20 18 0.0216 0.022 8.1
4 babu 63/M 2 WKS INSULIN NPDR4+CSME NPDR4 0.26 0.24 16 16 0.022 0.022 6.9
5 rajaram 45/M 17 YRS OHA+ISN PDR PDR 0.19 0.19 18 18 0.022 0.0218 7.4
6 kandasamy 46/M 15 YRS OHA+ISN PDR PDR 0.22 0.17 16 18 0.0216 0.0216 8
7 senthil 40/M 10 YRS OHA+ISN PDR+CSME PDR+CSME 0.18 0.22 18 16 0.0217 0.0217 7.9
8 jaithan bee 45/F 13 YRS OHA NPDR2+CSME NPDR2+CSME 0.22 0.22 18 18 0.0215 0.0215 6.8
9 sunitha bee 45/F 10 YRS OHA NPDR3+CSME NPDR3+CSME 0.24 0.22 16 18 0.022 0.022 6.8
10 kokila 54/F 15 YRS OHA NPDR3+CSME NPDR3+CSME 0.22 0.24 18 16 0.0216 0.0216 7.1
11 kurshith banu 53/F 10 YRS OHA+ISN NPDR4+FCSME NPDR4+DCSME 0.26 0.24 16 16 0.0217 0.0215 6.7
12 kasthuri 60/F 7 YRS OHA NPDR2+CSME NPDR2+CSME 0.24 0.24 16 16 0.0215 0.0215 6.9
13 anthony 40/F 3 MTHS OHA NPDR1 NPDR1 0.22 0.26 18 16 0.0215 0.0215 6.4
14 meenakshi 37/F 10 YRS OHA+ISN PDR PDR 0.19 0.17 18 18 0.022 0.022 8.1
15 sathyavathy 60/F 20 YRS OHA NPDR2+CSME NPDR2+CSME 0.22 0.24 18 16 0.0216 0.0216 6.4
16 kalikambal 70/F 3 YRS OHA NPDR2 NPDR2 0.24 0.26 16 16 0.0217 0.0216 6.2
17 sujatha 39/F 1 WK 0HA NPDR1 NPDR1 0.22 0.2 18 20 0.0214 0.0214 6.7
18 madeshwaran 30/M 16 YRS OHA NPDR2+CSME NPDR2+CSME 0.22 0.26 18 18 0.0215 0.0215 6.9
19 devikha 52/F 12 YRS OHA+ISN PDR PDR 0.19 0.19 18 18 0.0214 0.0214 8.3
20 kamala 50/F 4 YRS OHA NPDR2 NPDR2 0.26 0.24 16 16 0.022 0.022 6.1
21 meena 50/F 13 YRS OHA+ISN NPDR4 NPDR4 0.18 0.18 18 18 0.0217 0.0217 7.3
22 kumar 39/M 7 YRS OHA NPDR2 NPDR2 0.26 0.22 16 18 0.0214 0.0214 6.2
23 rajendran 49/M 12 YRS OHA NPDR3+CSME NPDR3+CSME 0.22 0.24 18 16 0.0216 0.0216 7.1
24 sangeetha 35/F 7 YRS OHA+ISN PDR+VH PDR+VH 0.22 0.24 16 16 0.0216 0.0216 7.5
25 roopavathy 60/F 20 YRS OHA NPDR3+CSME NPDR3+CSME 0.24 0.26 16 14 0.0215 0.0217 5.9
26 gunasekar 50/M 17 YRS INSULIN PDR+CSME PDR+CSME 0.17 0.18 20 18 0.0216 0.0216 7.9
27 dhanalakshmi 60/F 13 YRS INSULIN NPDR3 NPDR3 0.2 0.19 18 20 0.0217 0.0217 7.4
28 poochendu 65/F 16 YRS INSULIN PDR+CSME PDR+CSME 0.18 0.18 18 18 0.0215 0.0215 7.9
29 deepak kadir 60/M 10 YRS OHA+ISN NPDR3 NPDR3 0.2 0.2 18 18 0.0214 0.0214 6.9
30 vahith 62/M 5 YRS OHA  NPDR3 NPDR3 0.26 0.26 16 16 0.0216 0.0217 6.6
31 uma 55/F 5 YRS OHA NPDR3 NPDR3 0.26 0.2 16 18 0.0217 0.0216 7.4
Stage of DR
AQ outflow Facility 
in mlit/min/mm hg  IOP in mm hg Ocular Rigidity
MASTER CHART 
S .NO NAME
Age in 
yrs/ Sex
Duration of DM 
from Diagnosis Treatment HbA1c
RE    LE     RE LE      RE     LE    RE     LE
Stage of DR
AQ outflow Facility 
in mlit/min/mm hg  IOP in mm hg Ocular Rigidity
32 maariyama 60/F 8 YRS OHA NPDR3 NPDR3 0.2 0.22 18 18 0.022 0.022 7.1
33 kowsalya 52/F 15 YRS OHA NPDR3 NPDR3 0.19 0.19 20 20 0.0216 0.0216 7.2
34 Vasantha kumar 54/M 1.5 YRS OHA NPDR2 NPDR2 0.22 0.26 18 16 0.0214 0.0214 6.6
35 beenali raj 49/M 7 YRS OHA NPDR3 NPDR3 0.2 0.19 18 18 0.0217 0.0217 6.9
36 noorjahan 39/F 12 YRS OHA+ISN NPDR3 NPDR3 0.19 0.19 18 18 0.0215 0.0217 7.1
37 mary 62/F 3 YRS OHA NPDR2 NPDR2 0.22 0.22 18 18 0.0214 0.0214 6.9
38 maragatham 57/F 11 YRS OHA NPDR3 NPDR3 0.26 0.26 16 16 0.0217 0.0216 5.9
39 yasodha 47/F 5 YRS OHA NPDR1 NPDR1 0.28 0.28 16 16 0.0214 0.0214 5.9
40 reeta 60/F 4 YRS OHA NPDR1 NPDR1 0.28 0.26 16 18 0.0216 0.0216 6.5
41 rani 54/F 7 YRS OHA+ISN PDR PDR 0.17 0.17 20 20 0.0215 0.0216 8.4
42 munusamy 40/M 5 YRS OHA NO DR NO DR 0.28 0.24 16 16 0.022 0.0221 5.4
43 vaiayanthi 35/F 11.5 YRS OHA NPDR3 NPDR3 0.26 0.28 16 18 0.0214 0.0214 6.9
44 sundar 55/M 12 YRS OHA+ISN NPDR4 NPDR4 0.19 0.18 16 18 0.0215 0.0216 7.1
45 Vanishree 48/F 7 YRS OHA+ISN PDR PDR 0.19 0.17 18 20 0.0216 0.0216 7.6
46 pichai 56/M 2 YRS OHA NPDR1 NPDR1 0.22 0.26 16 16 0.022 0.0219 6.1
47 selvam 64/M 1 YR OHA NPDR3 NPDR3 0.21 0.26 18 16 0.0216 0.0216 6.5
48 ravindran 49/M 6YRS OHA NO DR NO DR 0.28 0.24 16 18 0.0217 0.0217 5.9
49 arputham 67/M 1 YR OHA NPDR1 NPDR1 0.26 0.26 16 16 0.0215 0.0216 5.8
50 ramaiyah 58/M 8 YRS OHA NPDR2 NPDR2 0.22 0.2 18 20 0.0216 0.0216 7.2
51 shenbagam 54/F 14 YRS OHA NPDR2 NPDR2 0.22 0.22 18 20 0.0214 0.0214 7.1
52 muthumani 51/M 11 YRS OHA NPDR1 NPDR1 0.28 0.28 14 14 0.0217 0.0217 5.7
53 parvathy 48/F 5 YRS OHA NPDR1 NPDR1 0.24 0.24 18 18 0.0216 0.0216 6.4
54 veeraiyah 60/M 13.5 YRS OHA+ISN NPDR4 NPDR4 0.18 0.2 18 18 0.0217 0.0216 7.3
55 anushya 53/F 10YRS OHA+ISN NPDR4 NPDR4 0.24 0.19 16 18 0.0214 0.0214 6.9
56 vimaladevi 59/F 5 YRS OHA NPDR2 NPDR2 0.24 0.22 18 18 0.0217 0.0217 6.9
57 maari 58/M 5 YRS OHA NPDR1 NPDR1 0.26 0.2 16 18 0.0215 0.0215 6.1
58 maariyaman 60/M 8 YRS OHA NPDR1 NPDR1 0.28 0.28 14 14 0.0216 0.0216 5.9
59 kannan 60/M 5 YRS OHA NPDR2 NPDR2 0.26 0.28 16 14 0.0215 0.0215 6.2
60 shanmugam 49/M 3 YRS OHA NPDR1 NPDR1 0.19 0.2 20 20 0.0216 0.0216 7.1
61 narayanan 50/M 5 MTH OHA NPDR1 NPDR1 0.22 0.22 18 18 0.0217 0.0217 6.5
62 padma 50/F 1 YR OHA NPDR1 NPDR1 0.22 0.26 18 16 0.0216 0.0215 6.6
63 raman 65/M 2 YRS OHA NPDR2+CSME NPDR2+CSME 0.26 0.26 16 16 0.022 0.022 6.6
64 sussela 54/F 10 YRS OHA NPDR2+CSME NPDR2+CSME 0.19 0.2 20 18 0.0217 0.0217 6.7
65 devaki 55/F 3 YRS OHA NPDR1 NPDR1 0.22 0.22 20 18 0.0215 0.0215 6.7
S .NO NAME
Age in 
yrs/ Sex
Duration of DM 
from Diagnosis Treatment HbA1c
RE    LE     RE LE      RE     LE    RE     LE
Stage of DR
AQ outflow Facility 
in mlit/min/mm hg  IOP in mm hg Ocular Rigidity
66 lakshmi 58/F 6 YRS OHA NPDR1 NPDR1 0.28 0.26 14 16 0.0215 0.0216 6.1
67 shanthi 57/F 5 YRS OHA NPDR3 NPDR3 0.19 0.19 20 20 0.0214 0.0214 7.3
68 gowri 57/F 7 YRS OHA NPDR1 NPDR1 0.28 0.28 14 16 0.0216 0.0216 5.8
69 kamathilakam 62/F 5 YRS OHA NPDR1 NPDR1 0.26 0.28 14 14 0.022 0.022 5.4
70 lakshmi 46/F 10 YRS OHA NPDR3 NPDR3 0.19 0.26 18 16 0.0217 0.0216 6.6
71 michael raj 67/M 13 YRS OHA NPDR1 NPDR1 0.28 0.26 14 16 0.0215 0.0215 5.5
72 vellathai 70/F 1.5 YRS OHA NPDR4 NPDR4 0.18 0.17 20 18 0.0216 0.0216 7.1
73 vishalatchi 53/F 8 YRS OHA NPDR4 NPDR4 0.2 0.18 18 18 0.0216 0.0216 7.1
74 ramanappan 76/M 1 YRS OHA NPDR2 NPDR2 0.24 0.26 16 16 0.0217 0.0217 6.6
75 desammal 60/F 2 YRS OHA NO DR NO DR 0.26 0.28 16 14 0.0216 0.0216 6
76 subhulakshmi 53/F 2.5 YRS OHA NPDR2+CSME NPDR2+CSME 0.28 0.28 14 16 0.0217 0.0217 5.9
77 padmavathy 60/F 4 YRS OHA NPDR2+CSME NPDR2+CSME 0.28 0.28 14 14 0.0216 0.0216 5.4
78 vairamani 50/M 1 YRS OHA NPDR1 NPDR1 0.26 0.26 16 16 0.0214 0.0214 6.1
79 uma 48/F 3 YRS OHA NPDR1 NPDR1 0.24 0.22 16 18 0.022 0.022 6
80 kalyani 52/F 7 YRS OHA NPDR2 NPDR2 0.28 0.28 14 14 0.0217 0.0217 5.6
81 senjiappan 40/M 9MTH OHA NO DR NO DR 0.26 0.28 14 14 0.0216 0.0216 5.7
82 rajeshwari 60/F 5 YRS OHA NPDR2 NPDR2 0.26 0.28 16 16 0.0217 0.0216 5.9
83 dhanalakshmi 52/F 3.1 YRS OHA+ISN NPDR2 NPDR2 0.22 0.26 18 16 0.0215 0.0215 6.1
84 mallika 55/F 8 YRS OHA NPDR4 NPDR4 0.24 0.24 16 16 0.022 0.022 6.9
85 amudha 51/F 6 YRS OHA NPDR2 NPDR2 0.26 0.26 16 16 0.0216 0.0216 6.2
86 parvathy 68/F 6 MTH OHA NPDR4 NPDR4 0.18 0.17 18 20 0.0215 0.0215 7.5
87 kalaiarasar 50/M 10 YRS OHA NPDR2 NPDR2 0.22 0.26 18 16 0.0217 0.0216 6.6
88 krishnaraj 65/M 10.3  YRS OHA NPDR4 NPDR4 0.26 0.28 16 14 0.0214 0.0215 6.6
89 selvi 65/F 4 YRS OHA NPDR3 NPDR3 0.26 0.26 16 16 0.0216 0.0216 5.9
90 indirani 70/F 10 YRS OHA NPDR4 NPDR4 0.2 0.26 18 16 0.022 0.022 7
91 dhamayanthi 35/F 4 YRS OHA+ISN PDR PDR 0.24 0.2 16 18 0.0216 0.0217 8.5
92 padmavathy 40/F 7 YRS OHA+ISN NPDR4 NPDR4 0.18 0.26 20 16 0.0215 0.0215 7.1
93 manjula 34/F 8 YRS OHA NPDR4 NPDR4 0.26 0.26 16 16 0.0217 0.0216 6.5
94 israel 58/M 2 YRS OHA PDR PDR 0.17 0.19 20 18 0.0216 0.0216 8
95 shanthi 45/F 5 YRS OHA+ISN NPDR4 NPDR4 0.19 0.19 18 18 0.0217 0.0217 7.5
96 babu 54/M 3 YRS OHA NPDR3 NPDR3 0.21 0.2 18 18 0.0215 0.0215 7.1
97 kathavarayan 39/M 2 YRS OHA NO DR NO DR 0.24 0.26 16 16 0.0216 0.0216 6.01
98 thiruvaruleswari 64/F 14 YRS OHA+ISN PDR PDR 0.19 0.24 18 16 0.0215 0.0214 7.7
99 varadharajan 68/M 7 YRS OHA NPDR1 NPDR1 0.26 0.28 14 16 0.0217 0.0217 5.4
100 kathayee 61/F 4 YRS OHA NPDR2 NPDR2 0.26 0.26 16 16 0.0216 0.0216 6.4
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101 lakshmi 42/F 12 YRS OHA+ISN NPDR3 NPDR3+CSME 0.28 0.28 14 14 0.0217 0.0217 6.4
102 rajammal 70/F 7 YRS OHA+ISN NPDR3+CSME NPDR3+CSME 0.26 0.26 16 14 0.0216 0.0216 6.5
103 mohan 67/M 15 YRS OHA NPDR3+CSME NPDR3+CSME 0.26 0.26 16 16 0.022 0.022 6.1
104 vasu 40/M 8 YRS OHA NPDR2+CSME NPDR2+CSME 0.26 0.22 16 18 0.022 0.0217 6.6
105 govindraj 52/M 3 YRS OHA+ISN PDR PDR 0.17 0.18 20 20 0.0215 0.0217 8.6
106 vani 35/F 7 YRS OHA+ISN NPDR4 NPDR4 0.18 0.2 20 18 0.0214 0.0214 8
107 pankajavalli 40/F 6 YRS OHA NO DR NO DR 0.28 0.28 16 16 0.0216 0.0216 6
108 prema 48/F 4 YRS OHA NPDR4 NPDR4 0.24 0.24 16 16 0.0215 0.0215 6.8
109 amirtha kani 61/F 8 YRS OHA NPDR1 NPDR1 0.28 0.28 14 14 0.0216 0.0217 5.5
110 govindraj 62/M 12 YRS OHA NPDR3 NPDR3 0.26 0.26 16 16 0.0216 0.0216 5.9
111 faridhabanu 60/F 3 YRS OHA+ISN PDR PDR 0.24 0.2 16 18 0.0215 0.0215 8.9
112 kalamani 45/M 15 YRS OHA NO DR NO DR 0.28 0.28 16 16 0.022 0.022 5.9
113 thenmozhi 50/F 7 YRS OHA NO DR NO DR 0.28 0.28 14 14 0.022 0.022 6
114 balamurugan 52/M 8 YRS OHA+ISN NPDR4 NPDR4 0.26 0.26 16 16 0.0216 0.0217 6.2
115 srinivasan 49/M 4 YRS OHA NPDR3 NPDR3 0.24 0.26 16 16 0.0217 0.0217 6.5
116 raja 67/M 7.3 YRS OHA+ISN PDR PDR 0.2 0.19 18 18 0.0215 0.0215 7.8
117 aswin kumar 42/M 2 YRS OHA NO DR NO DR 0.28 0.26 14 16 0.0217 0.0216 6.25
118 rajeshwari 60/F 7 YRS OHA NO DR NO DR 0.26 0.28 16 14 0.0215 0.0215 5.3
119 sabya 46/F 3 YRS OHA NPDR1 NPDR1 0.28 0.28 14 14 0.0216 0.0216 5.1
120 swarnakumar 56/M 9 YRS OHA+ISN PDR PDR 0.19 0.24 18 16 0.0214 0.0214 8.1
121 rajaram 67/M 7 YRS OHA+ISN NPDR4 NPDR4 0.24 0.19 16 20 0.0215 0.022 7.7
122 latha 54/F  4 YRS INSULIN NPDR3 NPDR3 0.22 0.2 18 18 0.022 0.0215 7.2
123 karpagam 61/F 8 YRS OHA NO DR NO DR 0.26 0.26 16 16 0.0216 0.0217 5
124 sadiq basha 65/M 5 YRS OHA NO DR NO DR 0.24 0.24 18 18 0.0215 0.0215 6.1
125 keerthana 42/F 6 YRS OHA NO DR NO DR 0.24 0.2 18 20 0.022 0.022 6.4
126 vani 57/F 12 YRS OHA+ISN PDR PDR 0.17 0.17 20 22 0.0215 0.0215 8.3
127 pattamal 64/F 8 YRS OHA NO DR NO DR 0.26 0.28 16 16 0.0216 0.0217 5.4
128 krishnan 65/M  12 YRS OHA+ISN PDR PDR 0.24 0.24 16 16 0.0216 0.0216 7.9
129 ramanathan 54/M 10 YRS OHA NPDR1 NPDR1 0.22 0.22 18 18 0.0215 0.0215 6.6
130 jayalakshmi 55/F 12 YRS OHA+ISN NPDR4 NPDR4 0.2 0.17 18 18 0.0215 0.0215 7.2
131 selvaraj 43/M 3 YRS OHA NO DR NO DR 0.28 0.24 16 18 0.0216 0.0217 5.7
132 menakammal 67/F 4 YRS OHA NO DR NO DR 0.28 0.28 16 16 0.0215 0.0215 5.4
133 pachiammal 57/F 9 YRS INSULIN PDR PDR 0.17 0.19 20 18 0.022 0.022 7.1
134 jagadeesh 45/M 5 YRS OHA NO DR NO DR 0.28 0.26 16 16 0.0214 0.0214 5.9
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135 munuswamy 57/M 9 YRS OHA+ISN NPDR4 NPDR4 0.2 0.17 18 16 0.0215 0.0215 7.4
136 dilliammal 45/F 7.3 YRS OHA NO DR NO DR 0.22 0.24 18 16 0.0216 0.0216 6.1
137 srinivasan 55/M 10 YRS OHA+ISN NPDR4 NPDR4 0.18 0.18 16 18 0.0217 0.0217 7.6
138 kamala 61/F 12 YRS OHA NO DR NO DR 0.24 0.24 16 16 0.0215 0.0215 5.7
139 gopal rao 54/M 2 YRS OHA NO DR NO DR 0.26 0.26 16 16 0.0216 0.0216 5.4
140 baskar 56/M 7 YRS OHA+ISN PDR PDR 0.17 0.24 20 16 0.0215 0.0215 6.9
141 kesavan 67/M 7 YRS OHA NPDR4 NPDR4 0.26 0.26 16 16 0.0217 0.0217 6.6
142 moorthy 62/M 5 YRS OHA NO DR NO DR 0.22 0.2 20 20 0.022 0.022 6.9
143 palani 56/M 8 YRS INSULIN PDR PDR 0.24 0.28 16 14 0.0215 0.0215 6.7
144 kandasamy 49/M 5 YRS OHA NO DR NO DR 0.24 0.26 16 16 0.0214 0.0214 6.5
145 kalimuthu 58/M 12 YRS OHA NO DR NO DR 0.28 0.28 14 14 0.0216 0.0216 6.1
146 kannamal 68/M 11.7 YRS OHA+ISN NPDR4 NPDR4 0.22 0.24 18 16 0.0215 0.0215 7.6
147 manikam 63/M 9 YRS OHA NO DR NO DR 0.28 0.28 14 14 0.0217 0.0216 6.2
148 nagamma 54/F 8 YRS OHA+ISN PDR PDR 0.2 0.17 18 20 0.0215 0.0215 8.2
149 kumutha 63/F 11 YRS OHA NO DR NO DR 0.28 0.28 14 14 0.0214 0.0214 5.4
150 mathan kumar 55/M 8 YRS OHA+ISN PDR PDR 0.24 0.19 16 18 0.0216 0.0216 7.5
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1 shanmugam 7.1 7 6.4 NPDR1 NPDR1 NPDR1 NPDR1 NPDR1 NPDR1 0.19 0.21 0.2 0.2 0.22 0.22 20 18 18 20 18 18 NO NO NO NO NO NO NO NO NO NO NO NO
2 suseela 6.7 6.7 6.5 NPDR2 NPDR2 NPDR2 NPDR2 NPDR2 NPDR2 0.19 0.22 0.22 0.2 0.22 0.22 20 18 18 18 18 16 NO NO NO NO NO NO NO NO NO NO NO NO
3 dhanalakshmi 7.4 7.9 7.5 NPDR3 NPDR3 NPDR3 NPDR3 NPDR3 NPDR3 0.2 0.19 0.19 0.19 0.18 0.18 18 20 20 20 20 22 NO NO NO NO NO NO NO NO NO NO NO NO
4 kowsalya 7.2 7.3 7.1 NPDR3 NPDR3 NPDR3 NPDR3 NPDR3 NPDR3 0.19 0.2 0.2 0.19 0.19 0.2 20 18 18 20 20 20 NO NO NO NO NO NO NO NO NO NO NO NO
5 beenaliraj 6.9 7.1 LFU NPDR3 NPDR3 LFU NPDR3 NPDR3 LFU 0.2 0.2 LFU 0.19 0.2 LFU 18 18 LFU 18 18 LFU NO NO NO NO NO NO NO NO NO NO NO NO
6 noorjahan 7.1 7.1 7 NPDR3 NPDR3 NPDR3 NPDR3 NPDR3 NPDR3 0.19 0.19 0.2 0.19 0.19 0.2 18 18 20 18 18 20 NO NO NO NO NO NO NO NO NO NO NO NO
7 shanti 7.3 7.3 7.1 NPDR3 NPDR3 NPDR3 NPDR3 NPDR3 NPDR3 0.19 0.19 0.19 0.19 0.19 0.19 20 20 18 20 18 20 NO NO NO NO NO NO NO NO NO NO NO NO
8 lakshmi 6.6 6.8 LFU NPDR3 NPDR3 LFU NPDR3 NPDR3 LFU 0.19 0.19 LFU 0.26 0.24 LFU 18 18 LFU 16 18 LFU NO NO NO NO NO NO NO NO NO NO NO NO
9 dhanalakshmi 7.3 7.3 7 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.19 0.19 0.2 0.18 0.19 0.19 18 20 18 20 20 18 NO NO NO NO NO NO NO NO NO NO NO NO
10 meena 7.3 7.4 LFU NPDR4 NPDR4 LFU NPDR4 NPDR4 LFU 0.18 0.17 LFU 0.18 0.17 LFU 18 18 LFU 18 18 LFU NO NO NO NO NO NO NO NO NO NO NO NO
11 vellathai 7.1 7 7 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.18 0.19 0.19 0.17 0.19 0.19 20 18 18 18 18 18 NO NO NO NO NO NO NO NO NO NO NO NO
12 vishalatchi 7.1 7.2 LFU NPDR4 NPDR4 LFU NPDR4 NPDR4 LFU 0.2 0.19 LFU 0.18 0.18 LFU 18 18 LFU 18 18 LFU NO NO NO NO NO NO NO NO NO NO NO NO
13 parvathy 7.5 7.9 7.5 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.18 0.17 0.18 0.17 0.17 0.19 18 20 20 20 20 20 NO NO NO NO NO NO NO NO NO NO NO NO
14 padmavathy 7.1 7.4 7.5 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.18 0.18 0.17 0.26 0.22 0.22 20 20 20 16 18 18 NO NO NO NO NO NO NO NO NO NO NO NO
15 mariappa 7.1 7.4 7.4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.19 0.18 0.18 0.18 0.18 0.17 16 18 18 18 20 20 NO NO NO NO NO NO NO NO NO NO NO NO
16 sundar 7.3 7.7 7.9 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.18 0.17 0.17 0.2 0.17 0.17 18 22 22 18 22 24 NO NO NO NO NO YES NO NO NO NO NO YES
17 anushya 6.9 LFU LFU NPDR4 LFU LFU NPDR4 LFU LFU 0.24 LFU LFU 0.19 LFU LFU 16 LFU LFU 18 LFU LFU NO NO NO NO NO NO NO NO NO NO NO NO
18 shanthi 7.5 7.3 LFU NPDR4 NPDR4 LFU NPDR4 NPDR4 LFU 0.19 0.18 LFU 0.19 0.18 LFU 18 18 LFU 18 18 LFU NO NO NO NO NO NO NO NO NO NO NO NO
19 vani 8 8 8.3 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.18 0.16 0.16 0.2 0.18 0.17 20 24 24 18 20 24 NO NO YES NO NO NO NO NO YES NO NO NO
20 rajaram 7.7 7.5 7.7 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.24 0.22 0.22 0.19 0.19 0.18 16 16 18 20 22 22 NO NO NO NO NO NO NO NO NO NO NO NO
21 jayalakshmi 7.2 7.4 LFU NPDR4 NPDR4 LFU NPDR4 NPDR4 LFU 0.2 0.18 LFU 0.17 0.17 LFU 18 18 LFU 18 20 LFU NO NO NO NO NO NO NO NO NO NO NO NO
22 munusamy 7.4 7.2 LFU NPDR4 NPDR4 LFU NPDR4 NPDR4 LFU 0.2 0.2 LFU 0.17 0.17 LFU 18 18 LFU 16 20 LFU NO NO NO NO NO NO NO NO NO NO NO NO
23 srinivasan 7.6 7.4 7.4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 NPDR4 0.18 0.18 0.18 0.18 0.18 0.18 16 16 16 18 18 18 NO NO NO NO NO NO NO NO NO NO NO NO
24 gunasekar 8.1 7.8 7.8 PDR PDR PDR PDR PDR PDR 0.17 0.17 0.18 0.19 0.18 0.18 20 20 20 18 18 18 NO NO NO NO NO NO NO NO NO NO NO NO
25 rajaram 7.4 7.4 LFU PDR PDR LFU PDR PDR LFU 0.19 0.18 LFU 0.19 0.19 LFU 18 18 LFU 18 18 LFU NO NO NO NO NO NO NO NO NO NO NO NO
26 kandasamy 8 8 7.9 PDR PDR PDR PDR PDR PDR 0.22 0.22 0.22 0.17 0.18 0.18 16 16 18 18 18 18 NO NO NO NO NO NO NO NO NO NO NO NO
27 senthil 7.9 LFU LFU PDR LFU LFU PDR LFU LFU 0.18 LFU LFU 0.22 LFU LFU 18 LFU LFU 16 LFU LFU NO NO NO NO NO NO NO NO NO NO NO NO
28 devika 8.3 8.3 8.1 PDR PDR PDR PDR PDR PDR 0.19 0.19 0.19 0.19 0.19 0.17 18 18 18 18 20 20 NO NO NO NO NO NO NO NO NO NO NO NO
29 gunasekar 7.9 7.7 LFU PDR PDR LFU PDR PDR LFU 0.17 0.17 LFU 0.18 0.18 LFU 20 20 LFU 18 18 LFU NO NO NO NO NO NO NO NO NO NO NO NO
30 poochendu 7.9 7.9 8.1 PDR PDR PDR PDR PDR PDR 0.18 0.18 0.17 0.18 0.17 0.17 18 18 20 18 20 20 NO NO NO NO NO NO NO NO NO NO NO NO
31 rani 8.4 8.1 8.1 PDR PDR PDR PDR PDR PDR 0.17 0.16 0.17 0.17 0.17 0.17 20 20 22 20 20 20 NO NO NO NO NO NO NO NO NO NO NO NO
32 vanishree 7.6 7.7 LFU PDR PDR LFU PDR PDR LFU 0.19 0.18 LFU 0.17 0.17 LFU 18 18 LFU 20 20 LFU NO NO NO NO NO NO NO NO NO NO NO NO
33 thiruvaruleswari 7.7 LFU LFU PDR LFU LFU PDR LFU LFU 0.19 LFU LFU 0.24 LFU LFU 18 LFU LFU 16 LFU LFU NO NO NO NO NO NO NO NO NO NO NO NO
34 faridhabanu 8.9 8.3 8.5 PDR PDR PDR PDR PDR PDR 0.24 0.21 0.2 0.2 0.2 0.18 16 18 18 18 20 20 NO NO NO NO NO NO NO NO NO NO NO NO
35 dhamayanthi 8.5 8.2 8.4 PDR PDR PDR PDR PDR PDR 0.24 0.21 0.21 0.2 0.2 0.18 16 18 18 18 18 20 NO NO NO NO NO NO NO NO NO NO NO NO
36 govindraj 8.6 8.4 LFU PDR PDR LFU PDR PDR LFU 0.17 0.17 LFU 0.18 0.17 LFU 20 20 LFU 20 20 LFU NO NO NO NO NO NO NO NO NO NO NO NO
37 raja 7.8 7.4 LFU PDR PDR LFU PDR PDR LFU 0.2 0.2 LFU 0.19 0.19 LFU 18 18 LFU 18 18 LFU NO NO NO NO NO NO NO NO NO NO NO NO
38 swarnakumar 8.1 7.7 LFU PDR PDR LFU PDR PDR LFU 0.19 0.19 LFU 0.24 0.24 LFU 18 18 LFU 16 16 LFU NO NO NO NO NO NO NO NO NO NO NO NO
39 vani 8.3 8.3 LFU PDR PDR LFU PDR PDR LFU 0.17 0.17 LFU 0.17 0.17 LFU 20 22 LFU 22 22 LFU NO NO NO NO NO NO NO NO NO NO NO NO
40 pachiammal 7.1 LFU LFU PDR LFU LFU PDR LFU LFU 0.17 LFU LFU 0.19 LFU LFU 20 LFU LFU 18 LFU LFU NO NO NO NO NO NO NO NO NO NO NO NO
41 baskar 6.9 7.1 LFU PDR PDR LFU PDR PDR LFU 0.17 0.17 LFU 0.24 0.17 LFU 20 20 LFU 16 16 LFU NO NO NO NO NO NO NO NO NO NO NO NO
42 nagamma 8.2 8.3 LFU PDR PDR LFU PDR PDR LFU 0.2 0.19 LFU 0.17 0.17 LFU 18 18 LFU 20 20 LFU NO NO NO NO NO NO NO NO NO NO NO NO
43 mathankumar 7.5 LFU LFU PDR LFU LFU PDR LFU LFU 0.24 LFU LFU 0.19 LFU LFU 16 LFU LFU 18 LFU LFU NO NO NO NO NO NO NO NO NO NO NO NO
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0.45 
8.00 
8.50 
10 
09 
0.03 
0.03 
0.07 
0.07 
0.11 
0.11 
0.15 
0.15 
0.19 
0.19 
0.24 
0.23 
0.29 
0.28 
0.34 
0.33 
0.39 
0.39 
0.45 
0.45 
9.00 
9.50 
08 
08 
_ _ 0.11 
0.11 
0.15 
0.15 
0.19 
0.19 
0.23 
0.23 
0.28 
0.28 
0.33 _ _ 
10.00 07 _ _ 0.11 
 
0.15 
 
0.19 0.23  _ _ _ 
Direct determination of facility of aqueous outflow from schiotz 
scale reading( 7.5 GM WT ). 
(Courtesy Committee On Tonometry, American Academy Of 
Ophthalmology,1965) 
Initial  
reading 
IOP 
Mm 
H g 
                            Change from initial to final scale 
0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 
0.50 
0.75 
54 
52 
0.05 
0.05 
0.12 
0.12 
0.23 
0.21 
0.41 
0.36 
0.76 
0.63 
_ _ _ _ _ 
1.00 
1.25 
50 
48 
0.04 
0.04 
0.11 
0.10 
0.19 
0.17 
0.32 
0.29 
0.50 
0.44 
0.79 
0.65 
_ _ _ _ 
1.50 
1.75 
46 
44 
0.04 
0.04 
0.09 
0.09 
0.16 
0.15 
0.26 
0.24 
0.30 
0.34 
0.35 
0.48 
0.79 
0.67 
_ _ _ 
2.00 
2.25 
42 
41 
0.04 
0.04 
0.09 
0.09 
0.14 
0.14 
0.22 
0.20 
0.31 
0.29 
0.43 
0.39 
0.58 
0.52 
0.78 
0.68 
_ _ 
2.50 
2.75 
39 
37 
0.04 
0.04 
0.08 
0.08 
0.13 
0.13 
0.19 
0.18 
0.27 
0.25 
0.36 
0.33 
0.47 
0.43 
0.60 
0.54 
0.77 
0.68 
_ 
3.00 
3.25 
36 
34 
0.03 
0.03 
0.07 
0.07 
0.12 
0.12 
0.17 
0.17 
0.23 
0.22 
0.31 
0.29 
0.40 
0.37 
0.50 
0.46 
0.62 
0.57 
0.76 
0.69 
3.50 
3.75 
33 
31 
0.03 
0.03 
0.07 
0.07 
0.11 
0.11 
0.16 
0.16 
0.21 
0.21 
0.28 
0.26 
0.35 
0.33 
0.43 
0.41 
0.53 
0.49 
0.63 
0.59 
4.00 
4.25 
30 
29 
0.03 
0.03 
0.06 
0.06 
0.10 
0.10 
0.15 
0.15 
0.20 
0.19 
0.25 
0.25 
0.32 
0.30 
0.39 
0.37 
0.46 
0.44 
0.55 
0.52 
4.50 
4.75 
29 
27 
0.03 
0.03 
0.06 
0.06 
0.10 
0.10 
0.14 
0.14 
0.18 
0.18 
0.24 
0.23 
0.29 
0.28 
0.35 
0.34 
0.42 
0.40 
0.50 
0.47 
5.00 
5.25 
26 
25 
0.03 
0.03 
0.06 
0.06 
0.10 
0.10 
0.13 
0.13 
0.17 
0.17 
0.22 
0.22 
0.27 
0.27 
0.33 
0.32 
0.39 
0.38 
0.45 
0.43 
5.50 
5.75 
24 
23 
0.03 
0.03 
0.06 
0.06 
0.09 
0.09 
0.13 
0.13 
0.16 
0.16 
0.21 
0.21 
0.26 
0.26 
0.31 
0.31 
0.37 
0.36 
0.42 
0.41 
6.00 
6.25 
22 
21 
0.03 
0.03 
0.06 
0.06 
0.09 
0.09 
0.12 
0.12 
0.16 
0.16 
0.20 
0.20 
0.25 
0.25 
0.30 
0.29 
0.35 
0.34 
0.40 
0.39 
6.50 
6.75 
20 
19 
0.03 
0.03 
0.05 
0.05 
0.09 
0.09 
0.12 
0.12 
0.15 
0.15 
0.18 
0.18 
0.24 
0.24 
0.28 
0.28 
0.33 
0.33 
0.38 
0.38 
7.00 
7.50 
18 
17 
0.03 
0.03 
0.05 
0.05 
0.08 
0.08 
0.12 
0.12 
0.15 
0.15 
0.19 
0.19 
0.24 
0.23 
0.27 
0.27 
0.32 
0.31 
0.37 
0.36 
8.00 
8.50 
16 
14 
0.03 
0.03 
0.05 
0.05 
0.08 
0.08 
0.11 
0.11 
0.15 
0.15 
0.18 
0.18 
0.22 
0.22 
0.26 
0.26 
0.30 
0.30 
0.35 
9.00 
9.50 
13 
12 
0.03 
0.03 
0.05 
0.05 
0.08 
0.08 
0.11 
0.11 
0.15 
0.15 
0.18 
0.18 
0.22 
0.22 
0.25 _ _ 
10.00 11 0.03 0.05 0.08 0.11 0.14 0.18 _ _ _ _ 
 
